{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-024487","form_type":"8-K","ticker":"GNPX","cik":"0001595248","company_name":"Genprex, Inc.","filed_at":"2025-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.454621+00:00","generated_at":"2026-05-17T21:27:37.375967+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"medium","headline":"Genprex issues 2025 corporate update; two lung cancer trials ongoing","bullets":["Patient treatment continues in two lung cancer clinical trials.","Company highlights clinical milestones across oncology and diabetes programs.","CEO Ryan Confer cites progress and upcoming milestones for H2 2025 and beyond.","No specific financial results or enrollment numbers disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-024487","json":"https://secwatch.observer/filing/0001437749-25-024487.json","markdown":"https://secwatch.observer/filing/0001437749-25-024487.md","text":"https://secwatch.observer/filing/0001437749-25-024487.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595248/000143774925024487/0001437749-25-024487-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595248/000143774925024487/gnpx20250618d_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:27:37.375967+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}